Cancer Treatment Clinical Trials

A listing of Cancer Treatment medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 411 clinical trials
Featured trial
Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors (CARMEN-LC03)  

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progression free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

  • 134 views
  • 30 Nov, 2022
  • 5 locations
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of …

measurable disease
cancer chemotherapy
lung carcinoma
  • 9 views
  • 20 Oct, 2022
  • 72 locations
An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC) (daNIS-3)

The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti

  • 0 views
  • 21 Oct, 2022
  • 28 locations
Cardiovascular Outcome of Cancer Patients: The "GMEDICO Cohort" (GMEDICO)

clinical, biological and imaging factors associated with cardiovascular events under cancer treatment, in order to define a risk score including clinical, biological (biomarker) and imaging data.

  • 0 views
  • 12 Oct, 2022
  • 0 views
  • 28 Oct, 2022
  • 77 locations
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma

This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not receiving any other cancer treatment can

  • 0 views
  • 25 Oct, 2022
  • 50 locations
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole.

  • 2 views
  • 07 Oct, 2022
  • 10 locations
Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors (CARMEN-LC03)

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progression free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

measurable disease
squamous non-small cell lung cancer
docetaxel
platinum-based chemotherapy
cancer
  • 60 views
  • 27 Oct, 2022
  • 192 locations
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)

The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel) versus clinician's choice of enzalutamide or docetaxel, in subjects with metastatic castration-resistant prostate cancer post …

testosterone
bone scan
abiraterone
gonadotropin releasing hormone
gilbert's syndrome
  • 0 views
  • 04 Oct, 2022
  • 4 locations
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2)

To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with advanced non-small cell lung

  • 0 views
  • 04 Oct, 2022
  • 11 locations